{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:25:24Z","timestamp":1774416324483,"version":"3.50.1"},"reference-count":71,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/140137\/2018"],"award-info":[{"award-number":["SFRH\/BD\/140137\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/142486\/2018"],"award-info":[{"award-number":["SFRH\/BD\/142486\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/QUIQIN\/28662\/2017"],"award-info":[{"award-number":["PTDC\/QUIQIN\/28662\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UID\/BIA\/04050\/2019"],"award-info":[{"award-number":["UID\/BIA\/04050\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/4050\/2020"],"award-info":[{"award-number":["UIDB\/4050\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>KRAS mutations are one of the most frequent oncogenic mutations of all human cancers, being more prevalent in pancreatic, colorectal, and lung cancers. Intensive efforts have been encouraged in order to understand the effect of KRAS mutations, not only on tumor cells but also on the dynamic network composed by the tumor microenvironment (TME). The relevance of the TME in cancer biology has been increasing due to its impact on the modulation of cancer cell activities, which can dictate the success of tumor progression. Here, we aimed to clarify the pro- and anti-inflammatory role of KRAS mutations over the TME, detailing the context and the signaling pathways involved. In this review, we expect to open new avenues for investigating the potential of KRAS mutations on inflammatory TME modulation, opening a different vision of therapeutic combined approaches to overcome KRAS-associated therapy inefficacy and resistance in cancer.<\/jats:p>","DOI":"10.3390\/cells11030398","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T20:44:33Z","timestamp":1643143473000},"page":"398","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2608-6511","authenticated-orcid":false,"given":"Fl\u00e1via","family":"Pereira","sequence":"first","affiliation":[{"name":"Centre of Molecular and Environmental Biology (CBMA), Department of Biology, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"},{"name":"Institute of Science and Innovation for Bio-Sustainability (IB-S), Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"},{"name":"Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal"},{"name":"Institute of Biomedical Engineering (INEB), University of Porto, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1417-3418","authenticated-orcid":false,"given":"Anabela","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Centre of Molecular and Environmental Biology (CBMA), Department of Biology, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"},{"name":"Institute of Science and Innovation for Bio-Sustainability (IB-S), Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-6639","authenticated-orcid":false,"given":"Celso Albuquerque","family":"Reis","sequence":"additional","affiliation":[{"name":"Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal"},{"name":"Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9424-4150","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Sousa","sequence":"additional","affiliation":[{"name":"Centre of Molecular and Environmental Biology (CBMA), Department of Biology, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"},{"name":"Institute of Science and Innovation for Bio-Sustainability (IB-S), Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0724-0272","authenticated-orcid":false,"given":"Maria Jos\u00e9","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal"},{"name":"Institute of Biomedical Engineering (INEB), University of Porto, 4200-135 Porto, Portugal"},{"name":"Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0630","authenticated-orcid":false,"given":"Ana","family":"Preto","sequence":"additional","affiliation":[{"name":"Centre of Molecular and Environmental Biology (CBMA), Department of Biology, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"},{"name":"Institute of Science and Innovation for Bio-Sustainability (IB-S), Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cazzanelli, G., Pereira, F., Alves, S., Francisco, R., Azevedo, L., Dias Carvalho, P., Almeida, A., C\u00f4rte-Real, M., Oliveira, M., and Lucas, C. (2018). The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis. Cells, 7.","DOI":"10.3390\/cells7020014"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4155\/fmc.11.121","article-title":"Inhibition of Ras for cancer treatment: The search continues","volume":"3","author":"Baines","year":"2011","journal-title":"Future Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the untargetable KRAS in cancer therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1101\/gad.1549407","article-title":"Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis","volume":"21","author":"Ancrile","year":"2007","journal-title":"Genes Dev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4161\/cc.5.15.3128","article-title":"Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders","volume":"5","author":"Kratz","year":"2006","journal-title":"Cell Cycle"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","unstructured":"Ihle, N. (2012). Differential Activity of the KRAS Oncogene by Method of Activation: Implications for Signaling and Therapeutic Intervention. [Ph.D. Thesis, The University of Texas]."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100186","DOI":"10.1016\/j.xcrm.2020.100186","article-title":"The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)","volume":"2","author":"Salgia","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s10555-020-09903-9","article-title":"Current therapy of KRAS-mutant lung cancer","volume":"39","author":"Ghimessy","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1535-7163.MCT-10-0262","article-title":"Galectin-3 Promotes Chronic Activation of K-Ras and Differentiation Block in Malignant Thyroid Carcinomas","volume":"9","author":"Levy","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bjc.6605534","article-title":"Activating K-Ras mutations outwith \u2018hotspot\u2019 codons in sporadic colorectal tumours\u2013implications for personalised cancer medicine","volume":"102","author":"Smith","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.gendis.2014.10.002","article-title":"Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer","volume":"2","author":"Knickelbein","year":"2015","journal-title":"Genes Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30787","DOI":"10.18632\/oncotarget.5021","article-title":"Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy","volume":"6","author":"Alves","year":"2015","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia","volume":"21","author":"Lee","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2016.09.008","article-title":"Molecular Pathogenesis of Pancreatic Cancer","volume":"144","author":"Grant","year":"2016","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1008794","DOI":"10.1080\/2162402X.2015.1008794","article-title":"The crosstalk between acinar cells with Kras mutations and M1-polarized macrophages leads to initiation of pancreatic precancerous lesions","volume":"4","author":"Storz","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","article-title":"KRAS mutation in pancreatic cancer","volume":"48","author":"Luo","year":"2021","journal-title":"Semin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hafezi, S., Saber-Ayad, M., and Abdel-Rahman, W.M. (2021). Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910219"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"21949","DOI":"10.1038\/srep21949","article-title":"The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B","volume":"6","author":"Lu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/JLB.5AB0220-608R","article-title":"Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study","volume":"108","author":"Polidoro","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.18632\/aging.202182","article-title":"KRAS mutations are negatively correlated with immunity in colon cancer","volume":"13","author":"Fu","year":"2021","journal-title":"Aging (Albany. NY)"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12153","DOI":"10.3390\/ijms131012153","article-title":"Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer","volume":"13","author":"Arrington","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1042\/BST20170521","article-title":"RAS in pancreatic cancer","volume":"47","author":"Lanfredini","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1200\/JCO.2004.02.154","article-title":"Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation","volume":"22","author":"Nagasaka","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_28","first-page":"5171","article-title":"KRAS mutation testing in metastatic colorectal cancer","volume":"18","author":"Tan","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1309\/AJCP7FO2VAXIVSTP","article-title":"KRAS Gene Mutation in Colorectal Cancer Is Correlated With Increased Proliferation and Spontaneous Apoptosis","volume":"135","author":"Liu","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_30","first-page":"932932","article-title":"EGFR Signaling in Colorectal Carcinoma","volume":"2011","author":"Krasinskas","year":"2011","journal-title":"Patholog. Res. Int."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Reinacher-Schick, A., Schulmann, K., Modest, D.P., Bruns, N., Graeven, U., Jaworska, M., Greil, R., Porschen, R., Arnold, D., and Schmiegel, W. (2012). Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-349"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"a031849","DOI":"10.1101\/cshperspect.a031849","article-title":"Kras and Tumor Immunity: Friend or Foe?","volume":"8","author":"Cullis","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-15-2840","article-title":"IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras\u2013Mutant Lung Cancer","volume":"76","author":"Caetano","year":"2016","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Granville, C.A., Memmott, R.M., Balogh, A., Mariotti, J., Kawabata, S., Han, W., LoPiccolo, J., Foley, J., Liewehr, D.J., and Steinberg, S.M. (2009). A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005061"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.4049\/jimmunol.1600576","article-title":"Lung Cancer Subtypes Generate Unique Immune Responses","volume":"197","author":"Busch","year":"2016","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","article-title":"The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity","volume":"470","author":"Liu","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-14-3042","article-title":"Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer","volume":"75","author":"Qu","year":"2015","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Uras, I.Z., Moll, H.P., and Casanova, E. (2020). Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124325"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3389\/fphar.2021.688625","article-title":"The Role of Tumor Inflammatory Microenvironment in Lung Cancer","volume":"12","author":"Tan","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/351959","article-title":"Tumor Microenvironment: A New Treatment Target for Cancer","volume":"2014","author":"Tsai","year":"2014","journal-title":"ISRN Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2019.01.013","article-title":"KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK\/ERK pathway in pancreatic cancer","volume":"446","author":"Cheng","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pinto, A.T., Pinto, M.L., Velho, S., Pinto, M.T., Cardoso, A.P., Figueira, R., Monteiro, A., Marques, M., Seruca, R., and Barbosa, M.A. (2016). Intricate Macrophage-Colorectal Cancer Cell Communication in Response to Radiation. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160891"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.tcb.2017.06.003","article-title":"Metabolic Interactions in the Tumor Microenvironment","volume":"27","author":"Lyssiotis","year":"2017","journal-title":"Trends Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jocs.2015.02.004","article-title":"Parameter identification of chaotic systems using artificial raindrop algorithm","volume":"8","author":"Jiang","year":"2015","journal-title":"J. Comput. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/nbm.3066","article-title":"Non-invasive temperature mapping using temperature-responsive water saturation shift referencing (T-WASSR) MRI","volume":"27","author":"Liu","year":"2014","journal-title":"NMR Biomed."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.1038\/sj.onc.1208995","article-title":"Dual effect of KrasD12 knockdown on tumorigenesis: Increased immune-mediated tumor clearance and abrogation of tumor malignancy","volume":"24","author":"Smakman","year":"2005","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fang, C., Zhang, C., Zhao, W.-Q., Hu, W.-W., Wu, J., and Ji, M. (2019). Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: A case report. BMC Med. Genom., 12.","DOI":"10.1186\/s12920-019-0592-6"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Petanidis, S., Anestakis, D., Argyraki, M., Hadzopoulou-Cladaras, M., and Salifoglou, A. (2013). Differential Expression of IL-17, 22 and 23 in the Progression of Colorectal Cancer in Patients with K-ras Mutation: Ras Signal Inhibition and Crosstalk with GM-CSF and IFN-\u03b3. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073616"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: Weaving a tumorigenic web","volume":"11","author":"Grabocka","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/onc.2016.288","article-title":"Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma","volume":"36","author":"Murakami","year":"2017","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ijc.27644","article-title":"NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression","volume":"132","author":"Okayama","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3892\/or.2016.5323","article-title":"High concordance rate of KRAS\/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases","volume":"37","author":"Fujiyoshi","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Jo, P., K\u00f6nig, A., Schirmer, M., Kitz, J., Conradi, L.-C., Azizian, A., Bernhardt, M., Wolff, H.A., Grade, M., and Ghadimi, M. (2016). Heterogeneity of KRAS Mutation Status in Rectal Cancer. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153278"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS Alleles: The Devil Is in the Detail","volume":"3","author":"Haigis","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","article-title":"KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment","volume":"78","author":"Cardoso","year":"2018","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Bellio, H., Fumet, J.D., and Ghiringhelli, F. (2021). Targeting BRAF and RAS in Colorectal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13092201"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1073\/pnas.1319051111","article-title":"T helper 17 cells play a critical pathogenic role in lung cancer","volume":"111","author":"Chang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Dias Carvalho, P., Machado, A.L., Martins, F., Seruca, R., and Velho, S. (2019). Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors. Cancers, 11.","DOI":"10.3390\/cancers11122010"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zeitouni, D., Pylayeva-Gupta, Y., Der, C., and Bryant, K. (2016). KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers, 8.","DOI":"10.3390\/cancers8040045"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13046-018-0719-1","article-title":"Targeting KRAS in metastatic colorectal cancer: Current strategies and emerging opportunities","volume":"37","author":"Porru","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1038\/s41467-021-26214-x","article-title":"Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry","volume":"12","author":"Valand","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","article-title":"KRAS-Mutant non-small cell lung cancer: From biology to therapy","volume":"124","author":"Ferrer","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Boussios, S., Ozturk, M., Moschetta, M., Karathanasi, A., Zakynthinakis-Kyriakou, N., Katsanos, K., Christodoulou, D., and Pavlidis, N. (2019). The Developing Story of Predictive Biomarkers in Colorectal Cancer. J. Pers. Med., 9.","DOI":"10.3390\/jpm9010012"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41379-018-0114-7","article-title":"Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas","volume":"32","author":"Liu","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2020.09.004","article-title":"KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma","volume":"149","author":"Gao","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","article-title":"KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition","volume":"41","author":"Adderley","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-017-0268-8","article-title":"The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment","volume":"5","author":"Poon","year":"2017","journal-title":"J. Immunother. Cancer"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/3\/398\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:06:48Z","timestamp":1760134008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/3\/398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cells11030398"],"URL":"https:\/\/doi.org\/10.3390\/cells11030398","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]}}}